Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic Developments.

In the AML19 study, AML patients were randomized to receive Tludarabine, Cytarabine, Idarubicin, and G-CSF (FLAG-IDA) or DA (Daunorubicin/Cytarabine): relapse rate (RR) was significantly lower with FLAG-IDA than with DA (three-year RR 26% or 68%, respectively), and there was a clear trend of improved OS for patients with FLAG-IDA compared to DA (three-year OS 66% vs. 37%, respectively) [ 28 ].

also in 19,460 other papers

Overall survival of these patients was similar across the different KMT2A translocations, including those generating KMT2A/MLLT3 fusion; however, t(9;11)(p21.3;q23.3)/ KMT2A::MLLT3 AML had an almost significant improvement of RFS compared to other KMT2A translocations [ 25 ].

also in 1,858 other papers